The study will evaluate ReActiv8 compared to a patient’s optimal medical management, according to a news release. ReActiv8 is designed to help patients with intractable chronic low back pain.
The trial will be done at 25 centers in the U.S.
Mainstay Medical completes enrollment in spinal cord stimulator trial
Mainstay Medical completed enrollment for its randomized clinical trial for its ReActiv8 restorative neurostimulation device, according to an Aug. 29 news release.
Next Up in Spinal Tech
-
Investment firm Viscogliosi Brothers completed its acquisition of Stryker’s U.S. spine business, according to an April 1 news release. The…
-
Richard Mueller is the new president and CEO of Life Spine, according to an April 1 news release. Mr. Mueller…
-
Stryker CEO Kevin Lobo’s total compensation grew from $20.8 million in 2023 to just under $22 million in 2024, according…
Comments are closed.